New ageing trial includes creatine in personalised plan

Key Takeaways

• This is a trial protocol, not a results paper, so there are no efficacy findings yet.
• Creatine is included as a fundamental intervention alongside exercise, whey protein, sleep and diet support.
• The study is small and short: 20 participants over 8 weeks.
• Because the intervention is multimodal and personalised, it will not isolate creatine’s independent effect.
• The protocol is designed to test feasibility, adherence and safety, while informing a later 12-month randomised trial.
• For readers, the bigger takeaway is that creatine is being treated as a mainstream component of healthy ageing strategies, not just a sports supplement.

What this paper actually adds

The news here is not that creatine has been proven to improve healthy ageing in this study. It has not. This GeroScience paper is a clinical trial protocol, which means it describes what researchers plan to do, who they plan to enrol, what interventions participants will receive, and which outcomes they will track.

In this case, the PROMETHEUS protocol outlines an 8-week feasibility and exploratory study in 20 middle-aged-to-older participants. Creatine appears in the programme as one of several “fundamental interventions”, alongside whey protein, fucoidan, sleep and dietary recommendations, supervised exercise with an exergaming component, motivational interviewing, and cognitive behavioural therapy.

That matters because it shows how creatine is increasingly being positioned in ageing research: not as a stand-alone miracle ingredient, but as one component of a broader healthspan strategy. The investigators also plan a more personalised layer of care, adjusting interventions based on predefined “gerotypes” and interim response.

For readers who use or are considering creatine, the immediate practical takeaway is modest but meaningful: serious researchers see creatine as sufficiently established and relevant to include in a precision healthy-ageing framework. What this paper does not show is whether creatine improved muscle, cognition, immune markers, or adherence in these participants. We will need the trial results, and especially the planned longer randomised study, before making any claims beyond that.

How the PROMETHEUS trial is designed

PROMETHEUS is structured as a feasibility and exploratory trial, not a definitive efficacy test. Researchers plan to enrol 20 participants and follow them for 8 weeks, with outcomes centred on muscle strength and mass, immune function, cognitive performance, and practical markers such as adherence and completion.

The protocol uses two layers of intervention:

• Fundamental interventions: sleep and dietary recommendations; supplementation with whey protein, creatine, and fucoidan; supervised exercise including dual-task cognitive-physical exergaming; motivational interviewing; and cognitive behavioural therapy.
• Augmented interventions: personalised additions based on predefined gerotypes and on baseline performance. Depending on muscle mass, VO2 peak, and cognitive performance, participants may be prescribed urolithin A, nicotinamide mononucleotide, and/or a multivitamin-multimineral. Midway through, the plan allows dose escalation or adding ergothioneine if cognition does not improve adequately.

That design is ambitious, but it also makes interpretation harder. If participants improve, it will be difficult to know how much credit belongs to creatine versus exercise, protein, sleep support, behavioural coaching, or the other nutraceuticals. In other words, this is a study of a package, not of creatine in isolation.

Still, the protocol has a sensible purpose. It is meant to test whether this kind of tailored programme is safe, practical, and acceptable enough to justify a larger 12-month randomised controlled trial. That later trial, if completed, should be much more informative than the protocol itself.

Why creatine is in an ageing protocol at all

Creatine’s inclusion here is not random. The best-established role of creatine is to help support high-energy phosphate availability in tissues with large and fluctuating energy demands, especially skeletal muscle. In practical terms, that is why creatine monohydrate has long been studied for strength, lean mass, and exercise performance, particularly when paired with resistance training.

Those same themes matter in ageing. Loss of muscle mass and function is a major driver of reduced independence, lower exercise capacity, and frailty risk. A supplement that may support training quality or muscle-related adaptations is therefore highly relevant to healthy ageing research.

That broader evidence base is why major reviews and position statements continue to treat creatine monohydrate as the most studied form of creatine. It is also why creatine now appears routinely in creatine guides aimed not just at bodybuilders, but at older adults, women, and everyday exercisers.

At the same time, readers should keep two realities in view. First, the benefits seen in prior creatine research often depend on context, especially whether people are also doing progressive exercise. Second, this protocol goes well beyond creatine. It combines nutrition, supplementation, exercise, and behaviour-change tools in a tightly managed programme. So while creatine’s presence makes scientific sense, the PROMETHEUS paper does not establish that creatine is the key active ingredient in whatever outcomes may eventually be reported.

What it means in practice for people taking creatine

For most readers, this protocol does not change the basic practical playbook for creatine. The mainstream evidence still supports creatine monohydrate as the default choice, with a common maintenance approach of 3 to 5 g per day. Some people also use a loading strategy of about 20 g per day split into 4 doses for 5 to 7 days, then continue with a lower daily maintenance intake.

If your main goals are strength, training performance, and preserving or building muscle, the strongest evidence still points to pairing creatine with structured exercise and adequate protein intake. That pairing is very much in line with how PROMETHEUS was designed: creatine was not given in a vacuum, but alongside whey protein and supervised exercise.

For people comparing products, the study offers no reason to chase exotic forms. Monohydrate remains the evidence-first option, and our best creatine rankings, creatine brand reviews, and creatine product catalog are better guides than protocol papers for choosing a product.

As always, older adults with kidney disease, complex medical conditions, or extensive medication use should speak with a clinician before starting any supplement. But for generally healthy adults, creatine’s safety profile remains well supported in the literature, including reviews addressing common misconceptions about bloating, dehydration, cramps, and kidney concerns in healthy users. If you want to estimate a sensible daily amount, a creatine dosage calculator can help keep things simple.

The big limitations readers should not miss

The biggest limitation is straightforward: there are no outcomes yet. This is a protocol paper. It tells us what researchers intend to test, not what happened.

Even once results arrive, several features will limit what can be concluded. The planned sample is very small at 20 participants, and the intervention lasts only 8 weeks. That is enough to explore feasibility, adherence, and early outcome trends, but it is not ideal for making strong claims about long-term healthspan effects.

The intervention is also highly complex. Participants receive multiple overlapping supports, and some receive further tailored nutraceuticals based on baseline traits and mid-study response. That personalisation may be clinically interesting, but it complicates attribution. If cognition, strength, or immune markers improve, we still may not know whether creatine contributed meaningfully, whether exercise drove most of the change, or whether the combination matters more than any single part.

There is also no indication in the abstract of a placebo-controlled creatine comparison. Without that, this study cannot answer the question many readers care about most: does creatine itself make a measurable difference here?

So the right interpretation is careful optimism about the research direction, not excitement about a result that does not yet exist. The protocol is interesting because it embeds creatine in a modern precision-ageing model. It is not evidence that this exact creatine-containing programme works.

How this fits the broader creatine evidence

Placed in context, PROMETHEUS looks less like a disruptive finding and more like a sign of where the field is heading. The established creatine literature already supports monohydrate as a well-studied, generally safe supplement with consistent benefits for strength and high-intensity exercise performance, and with frequent use in muscle-focused interventions.

That is why this protocol feels plausible rather than surprising. It builds on a foundation laid by large evidence reviews and practice statements, including the International Society of Sports Nutrition position stand and later reviews addressing common questions and misconceptions. Readers who want that broader backdrop can start with Antonio et al. on common creatine questions and the earlier ISSN position stand.

What remains less settled is the size and consistency of creatine’s effects outside classic sports-performance settings, especially in complicated healthy-ageing programmes where exercise, protein, sleep, and behaviour support are all changing at once. That is precisely why protocol papers like this matter: they show which questions researchers think are now worth testing in more realistic, real-world combinations.

For Creatine Canada readers, the practical hierarchy has not changed. The core evidence still points first to monohydrate, sensible daily dosing, and pairing supplementation with training. PROMETHEUS adds strategic context: researchers are increasingly asking how creatine fits into comprehensive ageing-care models, not whether it belongs only in the gym bag.

Bottom line

The PROMETHEUS paper is newsworthy because it puts creatine inside a personalised healthy-ageing trial that also includes protein, exercise, sleep, diet, and behavioural support. That reflects how mainstream creatine has become in evidence-based performance and muscle-health thinking.

But the key point is just as important: this study has not reported results. It cannot tell us whether creatine improved muscle, cognition, immune function, or healthspan outcomes in these participants, and it cannot separate creatine’s effect from the rest of the programme.

So what should readers do with this? Treat it as a signal, not a verdict. The signal is that researchers consider creatine relevant enough to build into a precision ageing protocol. The verdict on whether this particular intervention works, and how much creatine contributes, will have to wait for the actual data.

Until then, the evidence-based advice stays familiar: if you use creatine, choose monohydrate, keep dosing simple, combine it with training and adequate protein, and be sceptical of any headline that claims this new paper proved more than it did.

PROMETHEUS by the numbers

• 20 planned participants — Small feasibility sample
• 8 weeks study duration — Short exploratory intervention
• 3-5 g/day common creatine maintenance intake — Mainstream monohydrate guidance
• 20 g/day common loading approach — Usually split into 4 doses for 5-7 days

Frequently Asked Questions

Sources & Further Reading

• Kreider et al. (2017), ISSN Position Stand: Safety and Efficacy of Creatine — JISSN
• Antonio et al. (2021), Common questions and misconceptions about creatine supplementation — JISSN